Brian R. Weston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brian R. Weston has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Manoop S. Bhutani
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas
44 shared publications - Alexander Semaan
Department of Surgery, University Hospital Bonn, University of Bonn, Bonn, Germany
38 shared publications Bret M. Stephens
38 shared publications- Jaewon James Lee
Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
38 shared publications - Jonathan Huang
Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
38 shared publications Maria E. Monberg
38 shared publications
Latest Publications
- Open Access
Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial
Background/Objectives: Immunotherapy (IO) has demonstrated survival benefits in metastatic gastroesophageal cancers, and current data supports perioperative IO in localized adenocarcinomas. Radiation may further enhance IO response through immunologic priming. This study evaluates the feasibility, safety, and preliminary efficacy of incorporating IO into a chemoradiation-based perioperative strategy for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Methods: This single-arm, phase I/II study enrolled adults with untreated, locally advanced, resectable gastric or GEJ adenocarcinoma between February 2019 and June 2023. The treatment protocol consisted of induction chemotherapy (oxaliplatin + 5-fluorouracil), induction IO (nivolumab + ipilimumab), concurrent immune-chemoradiation (nivolumab, 5-fluorouracil, and 45 Gy IMRT/VMAT), surgical resection, and adjuvant nivolumab for residual disease. Primary endpoints were safety and feasibility; secondary endpoints included the pathologic complete response (pCR), R0 resection rate, disease-free survival (DFS), overall survival (OS), and biomarker analysis. Results: In total, 30 patients were enrolled, and 23 underwent resection. Grade 4 treatment-related toxicities occurred in three patients (10%), including acute kidney injury, myocarditis/myositis/myasthenia gravis overlap syndrome, and neutropenia. Among surgical patients, the pCR rate was 39.1% (95% CI: 19.7–61.5%), and the intention-to-treat pCR rate was 30% (95% CI: 14.7–49.4%). R0 resection was achieved in 87% of cases. Median DFS among resected patients was 40.2 months (95% CI: 21.6–NE). Median OS was 43.7 months (95% CI: 30.7–NE), with 2-, 3-, and 5-year OS rates of 73.3%, 57.5%, and 47.9%, respectively. Conclusions: This multimodality approach incorporating IO with chemotherapy and chemoradiation demonstrated a manageable safety profile and an encouraging pCR rate, supporting further evaluation.
Open AccessPerioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial
Background/Objectives: Immunotherapy (IO) has demonstrated survival benefits in metastatic gastroesophageal cancers, and current data supports perioperative IO in localized adenocarcinomas. Radiation may further enhance IO response through immunologic priming. This study evaluates the feasibility, safety, and preliminary efficacy of incorporating IO into a chemoradiation-based perioperative strategy for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Methods: This single-arm, phase I/II study enrolled adults with untreated, locally advanced, resectable gastric or GEJ adenocarcinoma between February 2019 and June 2023. The treatment protocol consisted of induction chemotherapy (oxaliplatin + 5-fluorouracil), induction IO (nivolumab + ipilimumab), concurrent immune-chemoradiation (nivolumab, 5-fluorouracil, and 45 Gy IMRT/VMAT), surgical resection, and adjuvant nivolumab for residual disease. Primary endpoints were safety and feasibility; secondary endpoints included the pathologic complete response (pCR), R0 resection rate, disease-free survival (DFS), overall survival (OS), and biomarker analysis. Results: In total, 30 patients were enrolled, and 23 underwent resection. Grade 4 treatment-related toxicities occurred in three patients (10%), including acute kidney injury, myocarditis/myositis/myasthenia gravis overlap syndrome, and neutropenia. Among surgical patients, the pCR rate was 39.1% (95% CI: 19.7–61.5%), and the intention-to-treat pCR rate was 30% (95% CI: 14.7–49.4%). R0 resection was achieved in 87% of cases. Median DFS among resected patients was 40.2 months (95% CI: 21.6–NE). Median OS was 43.7 months (95% CI: 30.7–NE), with 2-, 3-, and 5-year OS rates of 73.3%, 57.5%, and 47.9%, respectively. Conclusions: This multimodality approach incorporating IO with chemotherapy and chemoradiation demonstrated a manageable safety profile and an encouraging pCR rate, supporting further evaluation.
- 27 March 2025
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 23  (1) , 1-9
Outcomes of Endoscopic Dilation for Radiation Therapy-Related Esophageal Stricture
- 27 March 2025
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 23  (1) , 1-9
Outcomes of Endoscopic Dilation for Radiation Therapy-Related Esophageal Stricture
- Open Access
Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall survival (OS). Building on the recent evidence that PD-1 inhibition plus chemotherapy improves the OS of patients with metastatic GEJ adenocarcinoma, we evaluated whether the application of this strategy in the neoadjuvant setting would improve the pathological response. This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab. The primary objective goal was to achieve 20% pathCR. From the twenty enrolled patients, eighteen underwent resection and two (10%, 95% CI: 1.24–31.7%) achieved pathCR. After a median follow-up duration of 40.7 months, 11 patients had disease recurrence and 10 had died. The median disease-free and OS were 28.8 (95% CI: 14.7, NA) and 38.6 months (95% CI: 30.5, NA), respectively. No treatment-related adverse events led to death. Although modified FOLFOX plus atezolizumab did not achieve the expected pathCR, an acceptable safety profile was observed. Our results support the continued development of a more refined strategy (neoadjuvant chemotherapy plus perioperative immunotherapy/targeted agents) with molecular/immune profiling in parallel.
Open AccessChemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall survival (OS). Building on the recent evidence that PD-1 inhibition plus chemotherapy improves the OS of patients with metastatic GEJ adenocarcinoma, we evaluated whether the application of this strategy in the neoadjuvant setting would improve the pathological response. This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab. The primary objective goal was to achieve 20% pathCR. From the twenty enrolled patients, eighteen underwent resection and two (10%, 95% CI: 1.24–31.7%) achieved pathCR. After a median follow-up duration of 40.7 months, 11 patients had disease recurrence and 10 had died. The median disease-free and OS were 28.8 (95% CI: 14.7, NA) and 38.6 months (95% CI: 30.5, NA), respectively. No treatment-related adverse events led to death. Although modified FOLFOX plus atezolizumab did not achieve the expected pathCR, an acceptable safety profile was observed. Our results support the continued development of a more refined strategy (neoadjuvant chemotherapy plus perioperative immunotherapy/targeted agents) with molecular/immune profiling in parallel.
- 8 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97  (6) , AB618
ANALYSIS OF TECHNICAL FAILURE IN POST-PANCREATICODUODENECTOMY PATIENTS UNDERGOING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY
- 8 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97  (6) , AB618
ANALYSIS OF TECHNICAL FAILURE IN POST-PANCREATICODUODENECTOMY PATIENTS UNDERGOING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55  (S 02) , S162
ERCP of uncertain benefit in cancer patients with large volume hepatic tumor burden: a tertiary referral cancer center experience. (Is the glass half empty or half full?)
Aims Cancer patients with large volume hepatic tumor burden (LVHTB), hyperbilirubinemia and bile duct obstruction are frequently referred for ERCP with uncertain benefit. In most cases a bilirubin of < 2mg/dL is needed for systemic chemotherapy. The aim of this study was to evaluate the outcomes of patients with LVHTB referred for ERCP. Methods A retrospective review was performed on all patients with LVHTB referred for ERCP from 7/2021-9/2022. LVHTB was defined as estimated >50% liver involvement as assessed by cross-sectional imaging. Appropriate candidates for ERCP were selected based on the presence of dilated bile ducts within the remnant liver amenable to endoscopic drainage. The primary outcomes included technical success (successful biliary stent placement), clinical success (bilirubin normalization <2mg/dL) and subsequent treatment eligibility. Results Of 170 patients with LVHTB referred, 81 (47.6%) underwent ERCP and 89 (52.4%) were declined. Technical success was 93.8% (76/81). Clinical success was 27.2% (22/81). Percutaneous transhepatic biliary drainage was subsequently performed in 14 with a clinical success of 14.3% (2/14). Only 21.0% (17/81) received subsequent chemotherapy treatment. The remainder went to hospice 72.8% (59/81) or did not follow-up 6.2% (5/81). To date, 76.5% (62/81) passed away within a median of 32days (range 8-383) after ERCP ([Table 1]). Conclusions Based on our experience, less than half of referrals with LVHTB are candidates for ERCP. Despite high technical success, only one in four patients will have adequate response to allow treatment. This information should prove useful to setting expectations of patients and referring providers. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55  (S 02) , S162
ERCP of uncertain benefit in cancer patients with large volume hepatic tumor burden: a tertiary referral cancer center experience. (Is the glass half empty or half full?)
Aims Cancer patients with large volume hepatic tumor burden (LVHTB), hyperbilirubinemia and bile duct obstruction are frequently referred for ERCP with uncertain benefit. In most cases a bilirubin of < 2mg/dL is needed for systemic chemotherapy. The aim of this study was to evaluate the outcomes of patients with LVHTB referred for ERCP. Methods A retrospective review was performed on all patients with LVHTB referred for ERCP from 7/2021-9/2022. LVHTB was defined as estimated >50% liver involvement as assessed by cross-sectional imaging. Appropriate candidates for ERCP were selected based on the presence of dilated bile ducts within the remnant liver amenable to endoscopic drainage. The primary outcomes included technical success (successful biliary stent placement), clinical success (bilirubin normalization <2mg/dL) and subsequent treatment eligibility. Results Of 170 patients with LVHTB referred, 81 (47.6%) underwent ERCP and 89 (52.4%) were declined. Technical success was 93.8% (76/81). Clinical success was 27.2% (22/81). Percutaneous transhepatic biliary drainage was subsequently performed in 14 with a clinical success of 14.3% (2/14). Only 21.0% (17/81) received subsequent chemotherapy treatment. The remainder went to hospice 72.8% (59/81) or did not follow-up 6.2% (5/81). To date, 76.5% (62/81) passed away within a median of 32days (range 8-383) after ERCP ([Table 1]). Conclusions Based on our experience, less than half of referrals with LVHTB are candidates for ERCP. Despite high technical success, only one in four patients will have adequate response to allow treatment. This information should prove useful to setting expectations of patients and referring providers. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Aneuploidy, TMB, Complexity Score, HRD_LST, HRD_LOH, and SCNA for individual samples, correlation of SCNA markers, and platinum response.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Aneuploidy, TMB, Complexity Score, HRD_LST, HRD_LOH, and SCNA for individual samples, correlation of SCNA markers, and platinum response.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Mutations called in matched samples comparing enriched vs. FFPE samples (n=2) and enriched vs. non-enriched samples (n=1)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Mutations called in matched samples comparing enriched vs. FFPE samples (n=2) and enriched vs. non-enriched samples (n=1)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Comparison of CLIA results and sequencing results for five tumor specimens and three PBMCs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Comparison of CLIA results and sequencing results for five tumor specimens and three PBMCs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
It contains supplementary figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
It contains supplementary figures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Patient cohort and clinicopathological characteristics
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Patient cohort and clinicopathological characteristics